Navigation Links
ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Date:11/28/2008

PARIS, November 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) for use in studying mouse models of human disease. These SpliceArray(TM) products help our clients accelerate and refine their therapeutic target discovery and validation efforts. Using our high resolution expression profiling analysis, we identify novel transcripts coding for new protein variants that may be involved in various genetic disorders such as oncology, central nervous system, or immune system disorders. This mouse SpliceArray(TM) products represent the achievement of more two years of work by our R&D team after the launch of the Human genome SpliceArray(TM) in 2007 and the rat genome SpliceArray(TM) earlier this year.

"ExonHit has added another important species to its target discovery services portfolio. This addition will expand our ability to service scientists who use the mouse as a disease model, as well as our own discovery programs for novel therapeutic targets and biomarkers," said John R. Jaskowiak, Executive Vice President of Molecular Diagnostics and Genomics Services at ExonHit Therapeutics.

"These new Mouse SpliceArray(TM) products will further accelerate the understanding of mechanism of action and ultimately boost the discovery and validation of new therapeutics for ExonHit, using the Mouse as a disease model system, especially in the fields of oncology and CNS disease; this unique approach enabling to save months of preclinical development time," stated Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics.

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role i
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Appoints a New Management Board
8. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
9. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
10. Loic Maurel Joins Exonhit Therapeutics to Become CEO
11. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... Now a team led by an engineer at Michigan ... that will let scientists slash the cost of one ... Syringe pumps are used to dispatch precise amounts of ... a reaction. They can also cost hundreds or even ... of Michigan Tech students published the library of free ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Silicon-valley Electronic ... with Digitaliza TXT , the latest addition to ... its Clinical Research Organization (CRO) Program, Clinovo further expands ... three days of ClinCapture training, we are now able ... CEO Ana Pulido. “We can also rely on Clinovo ...
(Date:9/17/2014)... 2014 A long-term retrospective study of ... (APBI) via interstitial brachytherapy suggests that women younger ... could be suitable to receive the treatment. Current ... these patients in the "unsuitable" category for APBI. ... meeting, Beaumont Health System,s Peter Y. Chen ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... to complement VAP advanced cholesterol profileORLANDO, Fla. and ... of the VAP Cholesterol Test, has announced the ... at ACC.09, the American College of Cardiology (ACC) ... more than a dozen new tests, including C-Reactive ...
... January, the industry seems to have taken a deep breath and a step ... cuts that were announced were mostly due to the overall economic difficulty facing ... ... to say the worst is past for health care, it does seem as ...
... Phase 3 programCRANBURY, N.J., March 28 Amicus Therapeutics ... from its ongoing Phase 2 extension study of its ... The results will be presented at the American College ... FL. Phase 2 Extension Study Overview: Twenty-six ...
Cached Biology Technology:Atherotech Unveils New Cardiometabolic Test Panels 2Atherotech Unveils New Cardiometabolic Test Panels 3The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 2Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 4Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 5
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Di Benedetto and Micaela Caramellino, two doctoral ... received recognition at a student poster event organized ... nano- and micro-sized drug particles. The New Jersey ... was the sponsor. In recent years, ...
... Technology Business Assessment Group will fund four faculty ... identified these one-year projects from a number of ... earlier this spring. Funding for the program ... Property Management, and is generated by royalties from ...
... released today in the online edition of Physiological Genomics finds ... sugary foods. The study offers the first evidence of the ... gene that controls sugar entry into the cells has ... foods high in sugar. The study was conducted ...
Cached Biology News:NJIT doctoral students receive recognition at poster competition 2OSU technologies funded for development 2OSU technologies funded for development 3Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3
Request Info...
Request Info...
Request Info...
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
Biology Products: